Pharmacyclics, Inc. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
51 Pages - GMD12105
$1,500.00

Summary

Global Markets Direct’s, ‘Pharmacyclics, Inc. - Product Pipeline Review - 2014’, provides an overview of the Pharmacyclics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharmacyclics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pharmacyclics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pharmacyclics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Pharmacyclics, Inc.’s pipeline products

Reasons to buy

- Evaluate Pharmacyclics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pharmacyclics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pharmacyclics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pharmacyclics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharmacyclics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pharmacyclics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Pharmacyclics, Inc. Snapshot 5
Pharmacyclics, Inc. Overview 5
Key Information 5
Key Facts 5
Pharmacyclics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Pharmacyclics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pharmacyclics, Inc. - Pipeline Products Glance 11
Pharmacyclics, Inc. - Late Stage Pipeline Products 11
Pre-Registration Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
Pharmacyclics, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Pharmacyclics, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Pharmacyclics, Inc. - Drug Profiles 16
ibrutinib 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
abexinostat hydrochloride 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
PCI-27483 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
BTK Inhibitor Program 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PCI-34051 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Pharmacyclics, Inc. - Pipeline Analysis 26
Pharmacyclics, Inc. - Pipeline Products by Target 26
Pharmacyclics, Inc. - Pipeline Products by Route of Administration 27
Pharmacyclics, Inc. - Pipeline Products by Molecule Type 28
Pharmacyclics, Inc. - Pipeline Products by Mechanism of Action 29
Pharmacyclics, Inc. - Recent Pipeline Updates 30
Pharmacyclics, Inc. - Dormant Projects 42
Pharmacyclics, Inc. - Discontinued Pipeline Products 43
Discontinued Pipeline Product Profiles 43
PCI-45292 43
Pharmacyclics, Inc. - Company Statement 44
Pharmacyclics, Inc. - Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
Pharmacyclics, Inc., Key Information 5
Pharmacyclics, Inc., Key Facts 5
Pharmacyclics, Inc. - Pipeline by Indication, 2014 7
Pharmacyclics, Inc. - Pipeline by Stage of Development, 2014 9
Pharmacyclics, Inc. - Monotherapy Products in Pipeline, 2014 10
Pharmacyclics, Inc. - Pre-Registration, 2014 11
Pharmacyclics, Inc. - Phase III, 2014 12
Pharmacyclics, Inc. - Phase II, 2014 13
Pharmacyclics, Inc. - Phase I, 2014 14
Pharmacyclics, Inc. - Preclinical, 2014 15
Pharmacyclics, Inc. - Pipeline by Target, 2014 26
Pharmacyclics, Inc. - Pipeline by Route of Administration, 2014 27
Pharmacyclics, Inc. - Pipeline by Molecule Type, 2014 28
Pharmacyclics, Inc. - Pipeline Products by Mechanism of Action, 2014 29
Pharmacyclics, Inc. - Recent Pipeline Updates, 2014 30
Pharmacyclics, Inc. - Dormant Developmental Projects, 2014 42
Pharmacyclics, Inc. - Discontinued Pipeline Products, 2014 43
Pharmacyclics, Inc., Subsidiaries 49

List of Figures
Pharmacyclics, Inc. - Pipeline by Top 10 Indication, 2014 7
Pharmacyclics, Inc. - Pipeline by Stage of Development, 2014 9
Pharmacyclics, Inc. - Monotherapy Products in Pipeline, 2014 10
Pharmacyclics, Inc. - Pipeline by Top 10 Target, 2014 26
Pharmacyclics, Inc. - Pipeline by Top 10 Route of Administration, 2014 27
Pharmacyclics, Inc. - Pipeline by Top 10 Molecule Type, 2014 28
Pharmacyclics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 29

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax